




## **SUPPLEMENTAL MATERIAL**

### **Supplemental material table of content:**


Supplementary Figure 1	p.S2
Supplementary Figure 2	p.S4
Supplementary Figure 3	p.S5



**Supplementary Figure 1:** Representative dot plots illustrating the gating strategy of (A) total cTfhs (CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>), CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>PD1<sup>+</sup>, CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>PD1<sup>+</sup>ICOS<sup>+</sup> and CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>PD1<sup>+</sup>CXCR3<sup>-</sup> cTfhs (left and middle panels); and (B) naïve (CD19<sup>+</sup>CD27<sup>-</sup>), memory (CD19<sup>+</sup>CD27<sup>+</sup>) and transitional (CD19<sup>+</sup>CD24<sup>high</sup>CD38<sup>high</sup>) B cells. Fluorescence Minus One (FMO) controls were used to determine the optimal gate position as displayed on right panels.



**Supplementary Figure 2: Representative cytometry dot plots at transplantation.** A) Representative dot plots of total cTfhs ( $CD4^+CD45RA^+CXCR5^+$ ) at day 0 for patients receiving pre-emptive transplantation, peritoneal dialysis and hemodialysis). B) Representative dot plots of  $CXCR5^+PD1^+$  (top) and  $CXCR5^+PD1^+CXCR3^-$  (bottom) cTfhs in patients who experienced an immunizing event (Yes), compared to those who did not (No). C) Representative dot plots of total cTfh from  $CD4^+$  lymphocytes for patients with class I anti-HLA antibodies (non DSA) (Yes) and those with none (No). D) Representative dot plots of  $CXCR5^+PD1^+ICOS^+$  cTfh subset in patients with class II non-DSA anti-HLA antibodies (Yes) and in patients with no anti-HLA antibody (No).



**Supplementary Figure 3:** No correlation was evidenced between freezing time (in years) and frequency of alive lymphocytes (upper panel) or total CD4<sup>+</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup> cTfh frequency (lower panel). P-values from Spearman correlation are indicated.